Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Figure 1 | Alzheimer's Research & Therapy

Figure 1

From: Photobiomodulation with near infrared light mitigates Alzheimer’s disease-related pathology in cerebral cortex – evidence from two transgenic mouse models

Figure 1

Time course of the natural development of cortical pathology in K3 and APP/PS1 mice. (A), (B), (C), (D), (E), (F) Micrographs of hyperphosphorylated tau labelling (red), using the AT8 antibody, in the neocortex (A to C) and hippocampus (D to F) of untreated K3 mice at 3 months (A, D), 6 months (B, E) and 12 months (C, F) of age. (G), (H), (I) Micrographs of amyloid-beta (Aβ) labelling (green), using the 6E10 antibody, in neocortex of untreated APP/PS1 mice at 3 months (G), 4.5 months (H) and 12 months (I) of age. Arrowheads indicate intraneuronal Aβ labelling, arrows indicate extracellular plaques. Comparable immunolabelling was achieved with the 4G8 antibody. Sections were co-labelled for glial fibrillary acidic protein (red), a marker of astrocytes. For all sections, nuclei were labelled with bisbenzimide (blue). Scale in (H) applies to (A) to (G).

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193